Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Can Fite Biopharma Ltd
CANF
AMEX
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.89
-0.0004
-0.02%
Ult. Agg.: Oct 20, 8:57 AM
$1.90
0.01
0.53%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Rapporto azionario
Privacy Manager
Can Fite Biopharma Financials
Can Fite Biopharma (CANF) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.43) by 13.29 percent. This is a 71.1 percent increase over losses of $(4.29) per share from
Benzinga Newsdesk
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday
U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can Fite Biopharma announces reverse split.
Avi Kapoor
Nasdaq Down 1%; Medtronic Earnings Top Views
Avi Kapoor
Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings
Avi Kapoor
PRO
Can-Fite BioPharma FY24 Net Loss $7.88M
Benzinga Newsdesk
PRO
Can-Fite BioPharma 1H EPS $(0.00), Same YoY; Revenue $316K Down From $392K YoY
Financial ResultsRevenues for the six months ended June 30, 2024 were $0.32 million compared to revenues of $0.39 million for the same period in 2023. Revenues for the six months ended June 30, 2024 and June 30, 2023
Benzinga Newsdesk
